Weight management in obese cancer patients during curative active treatment: protocol for the CANOBESE feasibility study Authors: Aina Llenas-Bladé, Marta Puig Figueras, Carla Padilla Padilla, Anna Esteve, Raul Zamora-Ros, Mireia Daura i Vidal, Cristian Ochoa-Arnedo, Sonia Pernas, Cristina Santos Vivas, Jesús Brenes, Laura Jiménez-Colomo, Leyre Asiain, Ernest Nadal, Lorena Arribas Published: 2026 ABSTRACT AbstractBackgroundObesity is highly prevalent among patients with cancer and is associated with increased risks of treatment-related complications, poorer oncological outcomes, and long-term morbidity. Despite this, current oncology nutrition guidelines primarily address malnutrition and provide limited direction for clinical management of patients with obesity. Intentional weight loss interventions during cancer treatment are uncommon, partly due to concerns about safety and feasibility. The CANOBESE study aims to address this evidence gap by evaluating the feasibility of implementing a structured, multimodal weight management programme for patients with obesity undergoing curative oncological treatment.MethodsThis single-arm feasibility trial will recruit 50 adult patients with a BMI ≥ 30 kg/m2 and newly diagnosed stage II–IV solid tumours receiving chemotherapy, radiotherapy, immunotherapy, targeted therapy alone, or in combination with curative intent. The intervention includes a personalized hypocaloric and high-protein diet, a supervised home-based aerobic and resistance exercise programme, and integrated behavioural support delivered throughout the programme, with psycho-oncological input when more intensive individualized support is needed. Follow-up will continue for the duration of active treatment (3–9 months). The study will evaluate feasibility by examining key aspects such as recruitment and retention rates, intervention adherence and fidelity, participant acceptability, and the completeness of data collection throughout the intervention period. Secondary outcomes include exploratory changes in weight, body composition, physical performance, dietary intake, quality of life, and inflammatory biomarkers. The broad eligibility criteria were selected to evaluate feasibility in a pragmatic real-world oncology setting, while predefined exclusions were used to reduce baseline nutritional risk and improve safety.DiscussionThe CANOBESE study represents one of the first efforts to assess whether a comprehensive lifestyle intervention can be effectively delivered to patients with obesity during curative cancer treatment. This protocol incorporates patient and public involvement, a multidisciplinary team approach, and real-world implementation considerations. Findings will inform the scalability of the intervention, characterize implementation challenges across a pragmatic oncology population, and guide the design of a future randomized controlled trial. The study is not intended to provide subgroup-specific clinical recommendations, but to generate feasibility data that may help refine tailored approaches to intentional weight management in oncology settings.Trial registrationClinicalTrials.gov identifier: NCT07058207. Registered on 9 July 2025. https://clinicaltrials.gov/study/NCT07058207.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s40814-026-01868-w.Keywords: Obesity, Cancer, Oncology treatment, Multimodal intervention, Exercise, Feasibility This protocol explores the feasibility of a multimodal weight loss programme—including dietary counselling, physical activity, and behavioural support—to patients with obesity during curative cancer treatment. This protocol explores the feasibility of a multimodal weight loss programme—including dietary counselling, physical activity, and behavioural support—to patients with obesity during curative cancer treatment. It addresses a critical gap in implementation research by evaluating the acceptability, adherence, and integration of a structured weight management programme within routine oncology practice. It addresses a critical gap in implementation research by evaluating the acceptability, adherence, and integration of a structured weight management programme within routine oncology practice. By focusing on feasibility, this study lays the groundwork for a future trial assessing the clinical impact of intentional weight loss on treatment tolerance and oncological outcomes. By focusing on feasibility, this study lays the groundwork for a future trial assessing the clinical impact of intentional weight loss on treatment tolerance and oncological outcomes. The findings have the potential to inform the refinement of scalable and tailored future interventions that support weight management in cancer care and promote the integration of lifestyle-based strategies. The findings have the potential to inform the refinement of scalable and tailored future interventions that support weight management in cancer care and promote the integration of lifestyle-based strategies. Background Obesity, defined as a body mass index (BMI) greater than 30 kg/m2, affected over 890 million adults worldwide in 2022 [1]. Overweight and obesity is expected to reach 3.80 billion by 2050, representing over half of the global adult population at that time. Its prevalence has increased globally in recent decades and is recognized as a major risk factor for at least 13 types of cancer as well as various comorbidities [2]. The link between preclinical obesity and increased cancer risk suggests that obesity-related carcinogenesis begins before clinically detectable abnormalities, highlighting the need for early risk identification [3]. Given its strong association with cancer incidence and progression, obesity represents a growing challenge in oncology [4]. According to the World Health Organization (WHO), cancer remains one of the leading causes of mortality, responsible for approximately 9.7 million deaths in 2022 [5]. Obesity contributes to both cancer development and poorer clinical outcomes such as chronic inflammation, metabolic dysregulation, and uncontrolled cell proliferation [6]. Despite these associations, the impact of weight management during cancer treatment remains an area of ongoing debate. While cancer care has historically prioritized preventing weight loss, preclinical studies suggest that caloric restriction could enhance treatment response [7], highlighting the need to investigate weight loss interventions in patients with obesity during treatment [8]. It is important to recognize whether weight loss is intentional or unintentional, since unintentional weight loss is usually related to muscle loss and nutritional deterioration, which negatively influences the prognosis and the quality of life of these patients [9, 10]. Paradoxically, some cancer treatments can also lead to progressive weight gain, which may obscure muscle loss and increase the risk of treatment-related complications [11]. This complexity underscores the need for tailored interventions that address both weight and body composition. Although a high BMI is generally associated with an increased cancer-related mortality and recurrence, some studies have suggested an “obesity paradox”, where overweight patients showed better survival outcomes [12, 13]. This paradox has contributed to the controversy about the role of weight loss during cancer treatment, underscoring the need for specific research on this topic [14]. In addition to weight and body composition management, physical activity plays a crucial role in oncology care [15]. Exercise has been shown to positively influence the tumour microenvironment, potentially reducing cancer growth and aggressiveness [16]. Moreover, structured physical activity programmes are well-tolerated and associated with improvements in aerobic capacity, muscle strength, and treatment-related fatigue [17]. Physical activity, even in advanced stages of cancer, enhances both physical and emotional well-being, becoming it an essential component of comprehensive cancer care [18]. A recent phase III trial further showed that structured exercise after adjuvant chemotherapy improves disease-free and overall survival in colon cancer patients [19]. Given the psychological impact of cancer treatments, emotional support also becomes essential for the well-being of cancer patients [20]. Anxiety, depression, and emotional distress are common among cancer patients, and these factors can further influence treatment adherence and outcomes. Psychological interventions, such as cognitive-behavioural therapy, have proven effective in reducing anxiety and depression, significantly improving cancer patients’ quality of life [21]. These approaches are crucial for enhancing the overall treatment experience and emotional adaptation of cancer patients [22]. Considering the increasing prevalence of obesity and its implications in cancer care, there is a pressing need to integrate weight management strategies into oncology treatment plans [8]. Although some randomized trials have demonstrated that intentional weight loss intervention prior to cancer surgery may positively affect tumour characteristics and metabolic outcomes [16, 23], the feasibility of implementing such strategies during active oncological treatment remains unexplored. We hypothesize that a multimodal weight management programme, including nutritional intervention and physical exercise with behavioural support, is feasible during curative cancer treatment in patients with obesity. Methods/design Study design The CANOBESE study is a single-arm feasibility trial designed primarily to evaluate the implementation, acceptability, safety, and practicality of delivering a multimodal weight management intervention in routine oncology care. Given the feasibility focus, the study was intentionally designed to include a pragmatic oncology population rather than homogeneous disease-specific subgroups. Exploratory clinical outcomes are included to inform the design of a future definitive trial rather than to establish subgroup-specific effectiveness. It consists of a multimodal weight management programme including a personalized hypocaloric and high-protein diet, a supervised home-based exercise programme, and behavioural support. The protocol has been reviewed and approved by the Bellvitge University Hospital Ethics Committee (PR079/25), corresponding to protocol version 1.0 (April 2025). Setting, participants, and recruitment This study will be conducted at the Catalan Institute of Oncology (ICO) in L’Hospitalet de Llobregat, Barcelona, Spain. This is a cancer centre reference for over 40% of Catalonia’s adult cancer population and diagnoses approximately 16,000 new cases annually. A total of 50 patients with obesity (BMI ≥ 30 kg/m2) and a newly diagnosed stage II–IV solid tumour undergoing treatment with curative intent will be enrolled. Broad eligibility criteria were selected deliberately to assess the feasibility, acceptability, recruitment, and delivery of the intervention in a pragmatic real-world oncology setting. At the same time, the protocol excludes tumour locations associated with a high baseline risk of malnutrition, restricts inclusion to patients with ECOG performance status 0–1, and excludes patients with recent clinically significant unintentional weight loss, in order to reduce clinically relevant heterogeneity and enhance safety. Assuming two eligible candidates per week and a 40% recruitment rate, recruitment is expected to be completed within 12 months. Patients will be eligible for inclusion if they meet the predefined inclusion and exclusion criteria detailed in Table 1. This feasibility study is not intended to generate subgroup-specific clinical recommendations. Instead, it aims to determine whether the intervention can be delivered and accepted across a clinically relevant oncology population, and to identify which patient or treatment characteristics should be considered for refinement of eligibility criteria in a future definitive trial. Table 1Inclusion and exclusion criteriaInclusion criteria• Adults (aged 18 or older) with pathologically confirmed malignant solid tumours, stage II–IV, scheduled for oncological treatment (chemotherapy, radiotherapy, immunotherapy, other targeted therapies, or in combination) with curative intent• Expected duration of oncological treatment ≥ 3 months• Body mass index (BMI) ≥ 30 kg/m2• Resident in province of Barcelona until completion of cancer treatment• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1• Availability of internet access or a smartphone capable of video callsExclusion criteria• Patients with >10% unintentional weight loss within 3 months• Diagnosis of melanoma or brain tumours• Tumour locations associated with high malnutrition risk (e.g. head and neck, upper gastrointestinal tract, or pancreatic cancers)• Surgery as the only treatment modality• Pregnancy or breastfeeding• Presence of another active malignancy• Current health or medical conditions affecting weight status (e.g. untreated hyperthyroidism or hypothyroidism)• Pre-existing medical conditions that prevent safe, unsupervised exercise (e.g. severe orthopaedic disorders, scheduled hip/knee replacement, bone metastases, paralysis, dementia, untreated stage 3 hypertension, unstable angina, recent heart attack, congestive heart failure, or any condition requiring hospitalization or oxygen in the past 6 months)• Inability to read or understand Spanish or Catalan• Current enrolment in a weight loss programme• Active suicidal ideation, or presence of eating disorders (anorexia, bulimia, binge eating disorder), or substance abuse/dependence (excluding nicotine dependence)• Use of a pacemaker or any other implanted electrical device• History of bariatric or Lap Band surgery, or plans to undergo such procedures, including those currently on a waiting list• Any concurrent medical or psychological condition that, in the investigator’s judgement, could compromise patient safety or compliance with the protocol Inclusion and exclusion criteria • Adults (aged 18 or older) with pathologically confirmed malignant solid tumours, stage II–IV, scheduled for oncological treatment (chemotherapy, radiotherapy, immunotherapy, other targeted therapies, or in combination) with curative intent • Expected duration of oncological treatment ≥ 3 months • Body mass index (BMI) ≥ 30 kg/m2 • Resident in province of Barcelona until completion of cancer treatment • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1 • Availability of internet access or a smartphone capable of video calls • Patients with >10% unintentional weight loss within 3 months • Diagnosis of melanoma or brain tumours • Tumour locations associated with high malnutrition risk (e.g. head and neck, upper gastrointestinal tract, or pancreatic cancers) • Surgery as the only treatment modality • Pregnancy or breastfeeding • Presence of another active malignancy • Current health or medical conditions affecting weight status (e.g. untreated hyperthyroidism or hypothyroidism) • Pre-existing medical conditions that prevent safe, unsupervised exercise (e.g. severe orthopaedic disorders, scheduled hip/knee replacement, bone metastases, paralysis, dementia, untreated stage 3 hypertension, unstable angina, recent heart attack, congestive heart failure, or any condition requiring hospitalization or oxygen in the past 6 months) • Inability to read or understand Spanish or Catalan • Current enrolment in a weight loss programme • Active suicidal ideation, or presence of eating disorders (anorexia, bulimia, binge eating disorder), or substance abuse/dependence (excluding nicotine dependence) • Use of a pacemaker or any other implanted electrical device • History of bariatric or Lap Band surgery, or plans to undergo such procedures, including those currently on a waiting list • Any concurrent medical or psychological condition that, in the investigator’s judgement, could compromise patient safety or compliance with the protocol As shown in Table 1, tumour types with high baseline nutritional risk and patients with recent clinically significant unintentional weight loss are excluded to minimize the risk of confounding from pre-existing nutritional deterioration. Patients will receive the informed consent and the study information sheet from the dietitian. Once the consent is signed, the patient will be enrolled in the study. Patients who are not interested will be asked their reasons for disinterest. Intervention programme The intervention programme was clinically structured to support weight loss through well-defined components and delivery procedures, as illustrated in Fig. 1. Overview of the study design and components of each visit aligned with SPIRIT 2025 guidelines. Abbreviations: PET/CT scan: positron emission tomography/computed tomography scan; HADS: Hospital Anxiety and Depression Scale; 3DRF: 3-day food record; PG-SGA: Patient-Generated Subjective Global Assessment; CTCAE: Common Terminology Criteria for Adverse Events; DIET-SE: Dieting Self-Efficacy Scale Dietitian will give participants a 3-day food record (3-DFR) to complete prior to their baseline visit. After a full nutritional evaluation, the dietitian will create a personalized diet plan designed for each participant, using DietSource 4.0®, a specific software developed for the calculation and nutritional assessment of diets. According to the nutritional evaluation and their requirements [24], the dietary plan will be hypocaloric, with a 20% caloric restriction and high in protein (1.5 g of protein/kg/day) [25, 26]. The meal pattern will specify the number of “servings” for each food that is recommended per day. The dietitian will be able to make changes as needed. For those participants struggling to attain their recommended intake or expected to have difficulty meeting their protein requirements, an oral whey powder supplement will be provided throughout the duration of the study. Additional approaches to overcoming dietary challenges will include information/resources on nutritional symptom management that can impact dietary intake and/or high-protein recipes. The dietitian will visit the patient every 2 weeks, to give advice and support and monitor the patient’s weight loss progress. Physical function will be individualized by the physiotherapist prior to designing the exercise programme according to each participant’s clinical condition, treatment phase, and functional status. The physiotherapist will go over all the exercises with the patient and caregiver. Each patient will receive a fitness tracker band to monitor his/her physical activity during the entire study intervention. The exercise programme will be based on supervised aerobic and resistance exercise home-based training sessions, with a target frequency of 3 sessions per week. The target session structure will be approximately 60 min and include flexibility, aerobic, resistance, and balance exercises [27–29]. However, session duration, intensity, and specific exercise components may be adapted according to treatment-related symptoms, fatigue, tolerance, functional status, and temporary contraindications. When full sessions are not feasible, shorter sessions, lower-intensity alternatives, or temporary modifications will be used to preserve continuity and safety. The physiotherapist will supervise the sessions and provide monthly individual face-to-face counselling to assure adherence to the programme. Follow-up appointments will be scheduled every 2 weeks with the clinical dietitian and monthly with the physiotherapist until the completion of the oncological treatment, which is expected to last between 3 and 9 months. Behavioural support will be embedded throughout the intervention for all participants from the outset. The dietitian and physiotherapist will reinforce behaviour change strategies during follow-up visits, including motivational support, self-efficacy monitoring, and practical tools to address barriers related to eating behaviour, emotional eating, stress-driven behaviours, and exercise adherence. A psychologist will provide technical support and training to the dietitian and physiotherapist to strengthen delivery of these behaviour change components and to enhance motivation. Participants presenting greater behavioural or emotional barriers to adherence will additionally be offered individualized psycho-oncological assessment and targeted problem-solving support. The intervention protocol has been developed following the TIDieR checklist to ensure a comprehensive description of the intervention (see Additional file 1). In addition, the study design complies with the SPIRIT 2025 statement to define standard protocol items for clinical trials (see Additional file 2). Outcomes and data collection Primary outcome The primary outcome of the study is feasibility. This outcome will be assessed across multiple domains, summarized in Table 2, based on different frameworks [30–32] to determine whether the intervention can be delivered as intended within a routine clinical setting. Study data will be collected and managed using REDCap electronic data capture tools hosted at ICO [33]. All data will be anonymized to protect participant confidentiality and ensure compliance with data protection regulations. Table 2Summary of key implementation outcomes and their corresponding indicatorsImplementation outcomeStudy measuresRecruitment capabilityNumber of patients screened, proportion meeting eligibility criteria and the consent rate among eligible individuals, reasons for ineligibility or refusalAccrualWeekly enrolment rate, total time to achieve the target sample size and recruitment source for each serviceRetention and engagementAttendance at each visit monitoring (signature and annotation). Retention rate, dropout rate, time to drop out, reasons for drop outIntervention delivery feasibilitySession frequency and duration, room availability, staff workload compatibilityAcceptabilityPost-session feedback and satisfaction surveys and a final programme evaluation questionnaireData collection feasibilityCompleteness and quality of study data and the practicality of collecting key outcomes with minimal missing dataFidelity (protocol adherence)Fidelity checklist, DIET-SE, Treatment Self-Regulation Questionnaire, 24-h recall, 3-DFR. Adequacy will be calculated using a specific programme with recommended ranges between 85 and 115% of individual energy and protein requirements Summary of key implementation outcomes and their corresponding indicators Recruitment capability will be assessed by recording the number of patients screened, the proportion meeting eligibility criteria defined as the number of eligible participants by the number of participants assessed for eligibility, and the consent rate among eligible individuals defined by the number of participants who consented by the number of eligible participants. Reasons for ineligibility or refusal will be documented. These factors will help to determine whether the target population is accessible, and inclusion criteria are appropriate [31]. Accrual will be measured through the weekly enrolment rate calculated by dividing the number of new enrolments by the total enrolment target. Also, we will note the total time required to reach the target sample size. Recruitment source for each service will also be recorded to evaluate the consistency and reach of recruitment strategies. Retention and engagement will be evaluated by monitoring attendance at each visit using signed attendance sheet. We will calculate the retention rate defined by the number of participants who did not withdraw consent from study divided by the total number of enrolled participants. In addition, the dropout rate defined as the number of participants who dropped out to total number of participants enrolled. We will record the time to dropout and reasons for discontinuation [34, 35]. Intervention delivery feasibility will be assessed by evaluating session frequency and duration, room availability, and staff workload compatibility. These factors will inform whether the programme can be delivered consistently within existing clinical structures. Acceptability will be explored through brief post-session feedback and final programme evaluation questionnaires. Participants will be asked to reflect on the perceived burden of the intervention, its frequency and content, the behavioural support provided and their overall satisfaction, motivation, and perceived benefit. Data collection feasibility will be examined by assessing the completeness and quality of study data, as well as the practicality of collecting key outcomes with minimal missing data. Fidelity (protocol adherence) will be evaluated through session-specific fidelity checklists completed after each visit. Items will be scored as “1” if delivered as intended, “0” if omitted, and “−1” if inappropriate content is included [36]. If fidelity falls below 80%, retraining of the relevant team member (dietitian or physiotherapist) will be provided. Dietary adherence will be assessed through a self-perceived adherence scale (0–100%) and dietary intake measured by 24-h recall and 3-DFR records. Adequacy will be calculated using a specific programme with recommended ranges between 85 and 115% of individual energy and protein requirements. In addition, patient self-efficacy will be assessed as a fidelity outcome using a validated self-efficacy scale administered at the end of each session with both dietitian and physiotherapist. These scales reflect patient’s confidence for managing different scenarios of challenges to eating self-control and to exercising. This evaluation will be measured for both eating and exercise. Eating self-efficacy will be assessed using the scenario-based Dieting Self-Efficacy Scale (DIET-SE) [37]. The DIET-SE consists of 11 items, divided into three subscales that assess self-efficacy in managing different challenges to eating self-control. Divided into high caloric food (4 items), social and internal factors (4 items), and negative emotional events (3 items) [36]. Exercise self-efficacy will be assessed using the modified Physical Activity Self-Efficacy. It includes 18 items. Participants use a 5-point Likert scale, where 1= not at all confident and 5 = completely confident, to rate how confident they are that they will be able to exercise when “other things get in the way” such as being depressed, anxious, busy, or fatigued. A total score is calculated, and a higher score indicates higher self-efficacy for physical activity [38]. Autonomous motivation goals will be measured by an adapted and abbreviated version of the Treatment Self-Regulation Questionnaire. Four statements measuring autonomous motivation will be rated on a 5-point scale ranging from 1 (not at all true) to 7 (very true) [39, 40]. Examining autonomous motivation using this specific questionnaire will help to determine the need for one-to-one consultation with the psychologist. In addition to the feasibility outcomes, predefined progression criteria were established to determine whether it would be appropriate to proceed to a full-scale trial. These criteria provide an objective framework for interpreting the findings of pilot study and for identifying whether modifications to the intervention or study procedures are required prior to scaling up. Progression will be evaluated using a traffic-light system (green/amber/red), indicating whether each feasibility domain meets, partially meets, or fails to meet the predefined thresholds. The criteria define key feasibility aspects, including recruitment and retention capability, intervention delivery, acceptability, data collection, fidelity, and safety. Table 3 summarizes the predefined progression criteria and corresponding thresholds that will guide decisions on advancing to a definitive trial. Table 3Predefined traffic-light progression criteria across feasibility domains to guide decisions on progression to a definitive trialFeasibility domainGreenAmberRedRecruitment capability and accrual≥80% of target recruited within planned timeframe50–79% recruited or recruitment slower than expected<50% of target recruitedRetention and engagement≥85% retained70–84% retained<70% retainedIntervention delivery feasibility≥85% planned intervention sessions delivered as intended70–84% delivered<70% deliveredAcceptability≥80% positive feedback60–79% positive<60% positiveData collection feasibility≥90% of required data points collected accurately and on time70–89% data completeness<70% data completenessFidelity (protocol adherence)≥80% adherence to intervention and study procedures60–79% adherence<60% adherenceSafetyNo serious adverse events related to interventionMinor manageable eventsSerious adverse events related to intervention Predefined traffic-light progression criteria across feasibility domains to guide decisions on progression to a definitive trial If most feasibility domains meet the green criteria, the study will be considered feasible and suitable for progression to a full-scale trial without major modification. Domains rated amber will indicate partial feasibility, suggesting that minor procedural changes are required. A red rating in any critical domain will signify that redesign or reconsideration of the trial’s feasibility is necessary prior to implementation at scale. Secondary outcomes The secondary outcomes include exploratory changes in weight loss and body composition, dietary intake, quality of life, nutritional status, Mediterranean diet adherence, circulating blood biomarkers, and finally, safety reports. Weight and body composition Exploratory clinical outcomes will include changes at the end of the intervention in weight at, BMI, waist and hip circumference, and body composition (adipose tissue and muscle mass). We will descriptively examine the direction and variability of changes in body weight, adiposity, and muscle-related parameters in order to inform endpoint selection and design considerations for a future definitive trial. Anthropometric and body composition data will be collected at baseline and every 2 weeks at each dietetic session until the end of the oncological treatment (Fig. 1). The height measurement will be taken by placing the patient barefoot with feet together in an upright position and asking the patient to take a small breath in when the measuring rod is moved to record the height. To measure the weight, we will place the patient on the electronic scale (Seca® 704) with minimal clothing as possible. The patient will be also asked about his or her usual weight in relation to the last 6 months. With the weight and height, the BMI will be calculated. To measure the waist circumference, the subject will be asked to breathe normally, and the measuring tape will be placed about 0.5–1.0 cm above the navel. For measuring the hip circumference, the position of greatest circumference at the buttocks will be used [41]. Body composition will be analysed using the bio-electrical impedance analysis (BIA) (INBODY S10® segmental model) [42–44] at baseline and at every dietetic session. Because BIA estimates may be affected by treatment-related changes in hydration status, inflammation, or oedema, results will be interpreted cautiously and in conjunction with clinical assessment, weight trajectory, nutritional status, symptoms, and complementary body composition measures when available. This model reports the phase angle, a key indicator of cellular integrity [45]. Recently, the phase angle has been proposed as a marker of nutritional status in various clinical conditions, including obesity and cancer. A recent review concluded that the phase angle could serve as a health status marker in patients with obesity, supporting its use in weight management interventions to monitor body composition and preserve fat-free mass [46]. Moreover, muscle ultrasound will be measured to evaluate muscle and fat loss, in case of uncertainty with BIA [47]. Accordingly, BIA will be used as a pragmatic monitoring tool within routine care and not as a stand-alone reference method for diagnosing muscle loss. Body composition analysis for patients with staging positron emission tomography-computed tomography (PET/CT) scan or abdominal CT as part of their pre-treatment diagnosis procedure and at the evaluation response after treatment will also be included. The third lumbar (L3) vertebra will be chosen on the axial cross-section as the reference point, based on previous reports to calculate skeletal muscle index and total adipose tissue (including visceral and subcutaneous) [48, 49]. Low muscle mass (sarcopenia) will be defined according to Prado et al. criteria [50], specifically validated for obese cancer patients. For patients with available CT scans, skeletal muscle index will also be analysed as a complementary body composition measure. When BIA findings are uncertain or clinically discordant, available CT-based analysis and muscle ultrasound, where feasible, will support clinical interpretation. The REDCap database will generate alerts when clinically relevant or unexpected changes in weight or muscle-related parameters are detected during follow-up, prompting clinical review. These alerts are intended to support patient monitoring and safety, and not to serve as stand-alone diagnostic indicators of muscle loss. Physical function Secondary outcomes also include participant’s objectively measured physical function. This will be measured at baseline and every 4 weeks at each physiotherapy face-to-face session. Assessment of limb muscle strength will be taken with a digital manual hydraulic dynamometer, Jamar® brand, to measure the muscular strength of the upper limbs (right arm and/or left arm). Three measurements will be taken, always with the dominant hand, and the highest measurement will be used. Hand grip strength has frequently been utilized to evaluate physical function in oncology patients [51–53]. The evaluation of lower limbs will be done with the sit and stand-up test, evaluating the strength of the legs for 30 s (30-s Chair Stand). It is widely used and validated physical performance measure and has also been applied and evaluated in oncology populations [54–57]. Six-minute walking test will be done to evaluate the exercise tolerance capacity. The objective is to determine the submaximal exercise capacity walking on a flat surface for 6 min. Heart rate, oxygen saturation, dyspnoea, and fatigue will be monitored using the Borg scale of perceived exertion [58–61]. Each patient will receive a fitness tracker band to monitor his/her activity. Each device will be virtually connected to the physiotherapist who will monitor daily activity for each individual. In case of a sustained low activity, the patient will be contacted. Both physiotherapist and IT person will give technical support to the participants regarding the fitness tracker band. Nutritional status and intake A 24-h recall during the dietetic session and a 3-DFR brought by the patient at each visit will be collected to evaluate dietary intake. All food records will be then converted into nutrient intakes by a food composition software (DietSource 4.0®), and the participant’s calorie and nutrient intake will be assessed. The nutritional status of patients will be evaluated using the Patient-Generated Subjective Global Assessment (PG-SGA), a validated and widely utilized tool in oncology settings. The PG-SGA includes both patient-reported components—such as recent weight loss, dietary intake changes, nutrition-impact symptoms, and functional capacity—and clinician-assessed elements, including physical examination findings related to muscle and fat stores. Based on the total score, patients are classified as well-nourished (SGA A), moderately malnourished or suspected of malnutrition (SGA B), or severely malnourished (SGA C). The higher the score, the greater the risk of malnutrition [62]. Given that the study’s inclusion criteria only allow for the enrolment of patients who are well-nourished at baseline, any participant who becomes malnourished during the course of the intervention will be withdrawn from the study. In such cases, appropriate nutritional support will be provided outside the scope of the study, in accordance with standard clinical nutritional care. Lifestyle and mental health instruments The Mediterranean Diet Adherence questionnaire (14-Item Mediterranean Diet Adherence Screener, 14-MEDAS) [63] will be administered to determine adherence to the Mediterranean dietary pattern. This validated questionnaire consists of 14 items assessing the frequency of consumption of key components of the Mediterranean diet, such as olive oil, fruits, vegetables, legumes, fish, and wine, as well as the avoidance of non-Mediterranean foods like red meat and sugary beverages. Each item is scored as 0 or 1, depending on whether the dietary criterion is met, with a maximum score of 14 points. Higher scores indicate greater adherence to the Mediterranean diet. This tool is widely used in both clinical practice and epidemiological research to quickly and reliably assess dietary adherence in Mediterranean and non-Mediterranean population [64]. Quality of life will be assessed using two validated instruments. First, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), version 3.0, a widely used tool in oncology clinical trials. It consists of five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial impact), and a two-item global quality of life scale. This questionnaire provides a comprehensive assessment of both functional status and symptom burden, allowing the identification of key areas affecting patients’ quality of life during cancer treatment [65, 66]. In addition, the ORWELL 97 questionnaire will be administered to assess obesity-related quality of life. It is used in both clinical practice and research to evaluate the impact of obesity on well-being and to monitor treatment outcomes beyond weight loss. The ORWELL 97 is a validated self-report questionnaire that evaluates both the frequency and personal relevance of physical and psychosocial distress through 18 items. Higher scores reflect greater impairment [67]. The Hospital Anxiety and Depression Scale (HADS) will be used in the study to assess participants’ emotional state at both the beginning and the end of the intervention. This questionnaire consists of 14 items: 7 related to anxiety (HADS-A) and 7 related to depression (HADS-D). Each item is scored on a scale from 0 to 3, allowing for a total score out of 21 for each subscale. The HADS questionnaire has been validated in oncology settings, and it has proven to be a reliable and valid instrument for the identification and follow-up of anxiety and depression symptoms in oncology patients [68, 69]. Several studies have incorporated it into clinical practice with cancer patients [70]. Sociodemographic and lifestyle information, such as age, sex, smoking status, and alcohol consumption, and clinical variables, such as primary site and stage of the tumour, treatment scheme, and response, will be collected at baseline from the health clinical records. Safety Safety constitutes a critical component of feasibility assessment and clinical monitoring in this study. The clinical team will monitor safety and enable the identification of any adverse events or unintended consequences associated with the intervention, ensuring that its application does not compromise participant well-being. We will be especially interested in any serious or life-threatening event (defined as a physical or cardiac event which resulted in overnight hospitalization) that can be attributable to the intervention. Adverse effects will be recorded in the database. Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [71] and terminal events will be collected from the medical records. Circulating blood biomarkers As part of routine clinical care, blood samples will be collected from all participants during their standard oncological treatment procedures. These samples collected at baseline and final visit of the study will be allocated for additional research purposes, including inflammatory biomarkers at a later stage. The collected samples will be processed and stored under controlled conditions at the Infection and Cancer Laboratory (INCALAB) within the facilities of ICO, in an ultra-freezer, following ethical and regulatory guidelines. Sample size and statistical power For a feasibility study, a sample size of at least 50 subjects is recommended [72]. Considering that in our hospital there are approximately 120 patients potentially eligible for the study per year, a sample size of n = 50 subjects will allow us to estimate a recruitment rate of 40% [73] with a 95% confidence interval ±10% expecting to finish the recruitment in 12 months. This sample size will also allow us to estimate key feasibility parameters, including retention, adherence, safety, and completeness of data collection, with reasonable precision. Consistent with the aims of a feasibility study, the trial is not powered to test efficacy. Secondary clinical outcomes will be analysed descriptively to estimate variability and to inform endpoint selection and sample size assumptions for a future definitive trial. Efforts will be made to ensure a balanced representation of both sexes in order to identify which patients benefit most and to understand the limitations in those who do not. Statistical analyses Feasibility outcomes will be reported as proportions with 95% confidence intervals (CIs) where appropriate. Recruitment information will be included in the CONSORT flow diagram [31]. Weight and body composition, physical function, nutritional status and intake, lifestyle circulating blood biomarkers, and safety data at baseline and every 2 or 4 weeks will be analysed using descriptive statistics, as well as sociodemographic and clinical characteristics at baseline. Categorical data will be presented as frequencies and percentages, and continuous data will be presented as means and standard deviations. Questionnaire-based outcomes will be summarized using descriptive statistics. Continuous scores will be reported as means and standard deviations (or medians and interquartile ranges, as appropriate), and categorical data as frequencies and percentages. The percentage of missing data on each outcome measurement at each time point will be reported. Given the single-arm feasibility design and the expected clinical heterogeneity of the sample, analyses of secondary outcomes will be descriptive and exploratory, and no causal inference regarding the effect of the intervention on weight or body composition will be made. Baseline clinical and treatment-related heterogeneity will be carefully characterized. Where sample size allows, selected exploratory summaries may be presented by broad tumour or treatment categories to inform the design, stratification strategy, and eligibility criteria of a future definitive trial. The mean and paired 95% CIs for the pre- to post-intervention differences in weight and body composition will be reported. Log transformations for continuous variables will be applied when appropriate. These analyses will not be used for confirmatory inference or subgroup-specific recommendations. Result reporting will follow adapted guideline statements for quality and transparency publications [74]. Statistical analysis will be conducted using R (R Core Team, 2025) and RStudio (RStudio Team, 2025). Analyses will be predefined in a statistical analysis plan. Dissemination strategy The CANOBESE study aims to assess the feasibility and safety of a multimodal weight management intervention—including a personalized hypocaloric high-protein diet, supervised exercise, and behavioural support—for patients with obesity undergoing active cancer treatment. Dissemination of both the study protocol and its findings is a key element to ensure transparency, foster clinical integration, and prepare the ground for a larger randomized controlled trial evaluating clinical, metabolic, and quality of life outcomes. The dissemination strategy targets a broad audience, including oncology and nutrition clinical professionals, researchers, health system administrators, policymakers, and patient organizations. Scientific results will be shared via Open Access publications and presentations at a key national and international conferences. The team will also leverage institutional networks and repositories (e.g. ResearchGate, ICO, and IDIBELL platforms). At the clinical level, internal seminars and patient-orientated sessions will be conducted. Patient and public involvement is central to the strategy: the patient panel will contribute to the development of plain-language summaries and outreach materials which will be disseminated through patient associations and digital platforms with the support of institutional communication departments. Dissemination activities will be integrated throughout the study timeline. Early outputs will include protocol registration and internal presentations (months 3–6), followed by progress updates and preliminary findings shared with clinical teams and patient groups during the intervention phase (months 7–20). Data analysis and manuscript preparation will begin in the final quarter of the study (months 21–23), with broader dissemination—including scientific publications and conference presentations—planned from month 24 onwards. Engagement metrics, including article downloads, social media reach, and stakeholder feedback, will be monitored to evaluate dissemination impact and guide future communication strategies. Discussion The number of individuals affected by both cancer and obesity is rising rapidly, posing a significant challenge to cancer care. Obesity is associated with increased complications during oncological treatment and a higher risk of overall and cancer-specific mortality, recurrence, and cardiovascular events among cancer survivors [5, 75]. Recent research has highlighted the detrimental role of excess visceral adipose tissue in carcinogenesis and metabolic dysregulation [76]. Additionally, growing evidence supports the negative impact of reduced muscle mass in obese cancer patients on clinical outcomes, including overall survival [77]. Although oncology nutrition guidelines exist [78], they primarily focus on the prevention and treatment of malnourished patients and do not adequately address the specific needs of individuals with obesity undergoing cancer treatment. Currently, there are no nutritional guidelines specific for obese patients or those guidelines for clinical management in obese cancer patients do not include nutritional protocols [79, 80]. This study has the potential to serve as a foundational step toward the development of more tailored and evidence-informed approaches for patients with obesity undergoing cancer treatment. To date, approximately 20 weight loss trials have been completed across various oncology populations. The majority of these studies have focused on breast cancer survivors, showing significant reductions in adiposity and improvements in health-related quality of life, particularly in physical performance and fitness [81, 82]. The CANOBESE study marks an important step toward exploring whether a multimodal weight management intervention can be delivered safely and feasibly during the active phase of curative cancer treatment in patients with obesity. The broad and pragmatic eligibility criteria were chosen intentionally to reflect real-world oncology practice and to assess implementation across a clinically relevant population rather than within homogeneous disease-specific subgroups. This approach may improve the external relevance of feasibility findings, but it also introduces clinical and treatment-related heterogeneity that limits the interpretation of exploratory secondary outcomes and precludes subgroup-specific recommendations. For this reason, the present study is not intended to define clinical guidance for specific tumour or treatment sub-populations, but rather to identify implementation barriers, refine eligibility criteria, and inform the design of a future definitive randomized controlled trial. At the same time, the clinical heterogeneity of the sample must be considered when interpreting exploratory outcomes related to weight loss, body composition, and adherence, since the study is not designed or powered to assess differential effects across tumour types, stages, or treatment modalities. The study further includes exploratory assessments of inflammatory biomarkers, physical performance, and patient-reported outcomes, offering a multidimensional evaluation of the intervention. Participant self-motivation will also be monitored throughout the intervention to identify those who may benefit from additional psychological support. In addition to assessing feasibility as the primary objective, the study will also explore secondary clinical outcomes related to weight and body composition. These measures are included to estimate variability, assess measurement procedures, and generate data for the design of a future definitive trial. Given the absence of a control group, they will not be interpreted as evidence of intervention efficacy. A patient panel consisting of individuals with lived experience of cancer (either long-term survivors or patients currently undergoing extended oncological treatment) was established during the study development. This patient panel reviewed the proposal and provided feedback, particularly on the recruitment strategies and study design. Their involvement will continue throughout the study to support interpretation of implementation outcomes and identify barriers to adherence or questionnaire burden. In our comprehensive cancer centre, it is estimated that approximately two patients with a BMI ≥ 30 kg/m2 are diagnosed weekly, so the completion of targeted enrolment will be 1 year. We anticipate an 80% retention rate throughout the intervention, with at least 70% adherence to the dietary and physical activity components. Nevertheless, several challenges are anticipated. Recruitment may be affected by clinical burdens and staff workload. Adherence to dietary and exercise programmes can be difficult in this population, particularly in the presence of treatment-related symptoms such as fatigue, nausea, or psychological distress. For this reason, the exercise component is intended to be delivered flexibly and responsively according to symptom burden and treatment tolerance, and feasibility findings from the present study will help refine the optimal exercise dose and delivery format for a future definitive trial. The inclusion of behavioural support and continuous patient feedback throughout the intervention is designed to address these barriers, but some level of dropout or variation in compliance is expected. Assessment of autonomous motivation using this questionnaire will help determine the need for one-to-one consultation with the psychologist. However, people after cancer diagnosis are considered to be highly motivated to change their diet and lifestyles [83] and therefore, most people would be likely be receptive to the intervention to facilitate these changes. As a single-centre single-arm feasibility study with a relatively small sample size, the findings will not be generalizable to all cancer populations or healthcare settings. In addition, the absence of a control group limits the interpretation of changes in weight and body composition, since these may be influenced not only by the intervention but also by treatment-related toxicity, disease progression, or other concurrent clinical factors. Although BIA is feasible and practical for repeated monitoring, its interpretation during active cancer treatment requires caution because of potential interference from hydration and inflammatory changes. Furthermore, the study is not designed or powered to test efficacy. Rather, it is intended to generate feasibility data and exploratory estimates that will inform the design of a larger, well-structured randomized controlled trial in the future. We will also be able to determine recruitment and dropout rates, optimal visit frequency, preferred delivery modes (in-person or telephone), and implement any necessary adjustments throughout the study. The CANOBESE study will provide methodological advances for future studies on weight management during cancer treatment and essential feasibility data to support the refinement of tailored interventions for patients with obesity undergoing curative oncological treatment. Supplementary Information Additional file 1: SPIRIT 2025 checklist. Document containing the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) checklist, used to ensure that all essential items of a clinical trial are reported. Additional file 2: TIDieR (Template for Intervention Description and Replication) checklist, which helps describe interventions clearly and complete. Acknowledgements The authors would like to thank the World Cancer Research Fund International (WCRF) for supporting this project through the Pilot and Feasibility Grant Full 2024. IDIBELL acknowledges support from the Generalitat de Catalunya through the CERCA Program. We also thank the Patient and Public Involvement (PPI) panel for their valuable input in shaping the study. Special thanks to the Clinical Nutrition Unit, and to all oncologists, nurses, and administrative staff whose collaboration and support have been essential for enabling this project. Abbreviations Body mass index World Health Organization Catalan Institute of Oncology Eastern Cooperative Oncology Group Performance status 3-Day food record Positron emission tomography-computed tomography Hospital Anxiety and Depression Scale Patient-Generated Subjective Global Assessment Common Terminology Criteria for Adverse Events Dieting Self-Efficacy Scale Bellvitge Biomedical Research Institute Bio-electrical impedance analysis European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Infection and Cancer Laboratory Authors’ contributions LA conceived the study, led the protocol development, and is the principal investigator of the CANOBESE study. RZR and AE also led the protocol development, contributed to the study design, and provided clinical oversight and supervision of the conceptual framework. AE was additionally responsible for the statistical planning and analysis strategy. ALB, MPF, and CP contributed to the literature review and drafted the manuscript. ALB, LA, and RZR provided input on the design and implementation of the intervention. CO contributed expertise in psycho-oncology and behavioural support. MDV contributed physiotherapy expertise to the design of the exercise programme. SP, CSV, JB, LJC, LAs, EN, and LA supported the planning of patient recruitment and data collection strategies. RZR provided overall methodological supervision. All authors critically reviewed and approved the final version of the manuscript. Funding This study is supported by Grant Number PFG_FULL_2024_008 from the World Cancer Research Fund International (WCRF) under the Regular Grant Programme and Pilot and Feasibility Grant Full 2024. The content is solely the responsibility of the authors and does not necessarily represent the official view of the WCRF. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request and appropriate human subject approval. Declarations Ethics approval and consent to participate The CANOBESE study is approved by the Bellvitge University Hospital Ethics Committee (PR079/25). Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1: SPIRIT 2025 checklist. Document containing the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) checklist, used to ensure that all essential items of a clinical trial are reported. Additional file 2: TIDieR (Template for Intervention Description and Replication) checklist, which helps describe interventions clearly and complete. Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request and appropriate human subject approval.